Encouraging news: cancer mortality rates in the UK have reached a record low.
Based on the latest data from Cancer Research UK, between 2022 and 2024, approximately 247 individuals per 100,000 succumbed to cancer annually in the UK.
This figure marks a significant reduction from the peak of 355 deaths per 100,000 in 1989, signifying a nearly 29% decrease. Researchers attribute this sustained decline to decades of investment in cancer research, prevention, and treatment.
Substantial progress has been made in reducing deaths from several prevalent cancers. Over the last decade, stomach cancer deaths have decreased by 34%, lung cancer by 22%, ovarian cancer by 19%, breast cancer by 14%, and prostate cancer by 11%.
These improvements are the result of multiple factors working in concert. Advances in cancer screening, the availability of new and effective treatments, and earlier diagnoses have all contributed to enhanced survival rates.
In prostate cancer, for instance, hormone-based therapies have been instrumental in slowing tumor growth. The most notable progress has been seen in cervical cancer, with deaths declining by 75% since the 1970s, largely due to national screening programs and the introduction of the HPV vaccine.
Screening has played a crucial role in reducing cancer deaths. The NHS cervical screening program has been particularly successful in identifying cancers at an early stage, often detecting precancerous changes before cancer develops.
The introduction of the HPV vaccine in 2008, which has been administered to millions, has furthered this progress by preventing infections that could lead to cervical cancer.
Screening has also improved outcomes for other cancers. Programs for breast and colorectal cancer facilitate early detection, increasing the likelihood of successful treatment. Similarly, the advent of PSA testing has enhanced the detection of prostate cancer.
Simultaneously, advancements in cancer research have revolutionized treatment options. Targeted therapies and personalized medicine are becoming more widespread, enabling doctors to tailor treatments to the specific biology of a patient’s tumor. Hormone therapies that inhibit testosterone have notably improved prostate cancer outcomes.
Immunotherapy is also making significant strides. Researchers are investigating preventive vaccines for cancers such as lung and ovarian cancer, offering the potential to prevent these diseases before they manifest.
Public health initiatives have also contributed. Measures such as smoking bans and increased awareness of cancer risk factors have helped reduce death rates for several major cancers.
Despite the decline in cancer death rates, the total number of cancer-related deaths is rising due to the UK’s growing and aging population. As people live longer, the accumulation of mutations and cellular damage increases cancer risk.
The increase in deaths from certain cancer types is prompting researchers to shift focus. Many of these cases are associated with late-stage diagnosis as symptoms often emerge only in advanced stages. Expanding research and clinical trials in these areas could have a significant impact.
The cancers bucking the trend
Over the last decade, some cancers have seen an increase in mortality rates. Deaths from skin, intestinal, bone, gallbladder, and eye cancers have risen by 46%, 48%, 24%, 29%, and 26%, respectively. Liver cancer deaths have increased by 14%, while kidney cancer deaths are up by 5%.
Various factors contribute to these increases. Some cancers are challenging to detect early, and others lack effective treatments. Lifestyle choices, such as increased use of tanning beds and diets rich in ultra-processed foods, may also play a role.
Conversely, mortality rates for cancers like thyroid and pancreatic cancer, as well as some skin cancers, have remained largely stable.
Nonetheless, the general trend is positive. With ongoing investment in research, clinical trials, and NHS capacity, experts believe cancer mortality could decline further. Projections indicate a 6% reduction in death rates between 2024-26 and 2038-40 in the coming decades.
Related: US Cancer Survival Has Reached a Milestone High of 70%
While challenges persist, the latest statistics demonstrate the impact of sustained investment in research, prevention, and treatment. As screening advances, therapies progress, and prevention efforts grow, further strides in combating cancer appear promising.
Ahmed Elbediwy, Senior Lecturer in Cancer Biology & Clinical Biochemistry, Kingston University and Nadine Wehida, Senior Lecturer in Genetics and Molecular Biology, Kingston University
This article is republished from The Conversation under a Creative Commons license. Read the original article.
